Today, EnsoData and Aeroflow announce a strategic partnership to revolutionize personalized sleep apnea care using predictive clinical AI tools to enable more timely patient care, increase patient adherence, and strengthen the foundational provider-patient connection.
EnsoData’s PAP therapy adherence AI model, EnsoTherapy, supports and empowers Aeroflow’s sleep coaches with actionable data to provide rapid, personalized support to patients who are struggling with therapy adherence. EnsoTherapy’s task generation and smart-prioritization allow for more streamlined and logical patient: coach pairings and assignments, leading to improved patient compliance.
“Our PAP therapy prediction models accurately predict 30-, 60-, and 90-day patient compliance within days of starting treatment,” shares Sam Rusk, EnsoData Chief Artificial Intelligence Officer. “EnsoTherapy will have a transformative impact on the growing patient population who face challenges in treating their sleep apnea by enabling Aeroflow to better prioritize the patients in their network who struggle the most on therapy and have the greatest potential health and adherence benefit from targeted coaching and intervention. This collaboration will bring patients the best CPAP therapy onboarding experience possible and help them feel understood throughout their treatment journey while also demonstrating best-in-class adherence results. This is a true win-win for patients and for providers alike.”
The EnsoTherapy support and mentorship provided by EnsoData sleep coach Lacey Adams, RPSGT, CCSH, enabled a fast onboarding process for Aeroflow sleep coaches and allowed them to make an immediate impact with the program.
“Through EnsoData’s AI-powered technology, our team has already witnessed significant improvements in our ability to promptly deliver personalized support to the patients in greatest need. Though it is still early, we have already seen an uptick in the number of patients meeting their usage requirements within the initial 30 days. We are excited to see the outcomes at the 90-day mark. Compliance holds a deeper significance for us beyond mere numerical targets; it embodies our commitment to fostering improved health outcomes for our patients. EnsoTherapy unquestionably contributes to this mission,” said Joey Sasvari, Aeroflow, Director of Sleep.
Patients deserve a simple, effective experience from testing through treatment. The partnership between Aeroflow and EnsoData is a pivotal step toward improving the CPAP therapy onboarding process and increasing overall treatment compliance metrics, driven by the power of targeted, prioritized, and AI-enabled patient intervention.
Source: EnsoData
